Quality of Life in Sarcoidosis: Assessment and Management

ABSTRACT

This review focuses on current knowledge of the QOL (quality of life) and HS (health status) of sarcoidosis patients. The QOL and HS of sarcoidosis patients are impaired and symptoms are a cause of this impairment. Fatigue appears to be the major problem in sarcoidosis patients. QOL is a concept that concerns patients’ evaluation of their functioning in a wide range of domains, but always the physical, psychological, and social domain. HS concerns patients’ physical, psychological, and social functioning. There are a number of HS questionnaires and one QOL measure that have shown useful in sarcoidosis. In addition, there exists one sarcoidosis-specific HS measure. The main symptom of fatigue can be assessed reliably and valid with the Fatigue Assessment Scale.

The absence of objective parameters for experiencing impairment does not always mean that patients are healthy. Because what patients can handle is clearly decreased, the activities should be adapted accordingly.

Present studies are generally cross-sectional. There is a need for prospective follow-up studies assessing the natural course of patients’ disease in relation to symptoms and QOL.

KEYWORDS

Fatigue - sarcoidosis - quality of life - assessment - management

REFERENCES

• 1 Iannuzzi M C, Rybicki B A, Teirstein A S. Sarcoidosis.  N Engl J Med. 2007;  357 2153-2165
• 2 Wirnsberger R M, de Vries J, Wouters E F, Drent M. Clinical presentation of sarcoidosis in the Netherlands an epidemiological study.  Neth J Med. 1998;  53 53-60
• 3 Drent M, Wirnsberger R M, Breteler M H, Kock L M, de Vries J, Wouters E F. Quality of life and depressive symptoms in patients suffering from sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1998;  15 59-66
• 4 Wirnsberger R M, de Vries J, Breteler M H, van Heck G L, Wouters E F, Drent M. Evaluation of quality of life in sarcoidosis patients.  Respir Med. 1998;  92 750-756
• 5 De Vries J, Wirnsberger R M. Fatigue, quality of life, and health status in sarcoidosis.  European Respiratory Society Monograph. 2005;  32 92-104
• 6 Michielsen H J, Peros-Golubicic T, Drent M, De Vries J. Relationship between symptoms and quality of life in a sarcoidosis population.  Respiration. 2007;  74 401-405
• 7 Elfferich M D, Nelemans P J, Ponds R W, De Vries J, Wijnen P A, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-α treatment.  Respiration. 2010;  , Apr 29. [Epub ahead of print]
• 8 Bradley C. Importance of differentiating health status from quality of life.  Lancet. 2001;  357 7-8
• 9 Curtis J R, Patrick D L. The assessment of health status among patients with COPD.  Eur Respir J Suppl. 2003;  41 36s-45s
• 10 De Vries J, Seebregts A, Drent M. Assessing health status and quality of life in idiopathic pulmonary fibrosis: which measure should be used?.  Respir Med. 2000;  94 273-278
• 11 Breek J C, de Vries J, van Heck G L, van Berge Henegouwen D P, Hamming J F. Assessment of disease impact in patients with intermittent claudication: discrepancy between health status and quality of life.  J Vasc Surg. 2005;  41 443-450
• 12 Testa M A. Methods and applications of quality-of-life measurement during antihypertensive therapy.  Curr Hypertens Rep. 2000;  2 530-537
• 13 Montazeri A, Milroy R, Gillis C R, McEwen J. Quality of life: perception of lung cancer patients.  Eur J Cancer. 1996;  32A 2284-2289
• 14 World Health Organization .Facet Definition and Questions: Field Trial WHOQOL-100. Geneva; WHO 1995
• 15 The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization.  Soc Sci Med. 1995;  41 1403-1409
• 16 Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.  Psychopharmacol Bull. 1993;  29 321-326
• 17 Ritsner M, Kurs R, Kostizky H, Ponizovsky A, Modai I. Subjective quality of life in severely mentally ill patients: a comparison of two instruments.  Qual Life Res. 2002;  11 553-561
• 18 Guyatt G H, Berman L B, Townsend M, Pugsley S O, Chambers L W. A measure of quality of life for clinical trials in chronic lung disease.  Thorax. 1987;  42 773-778
• 19 Guyatt G H, Townsend M, Keller J, Singer J, Nogradi S. Measuring functional status in chronic lung disease: conclusions from a randomized control trial.  Respir Med. 1989;  83 293-297
• 20 Wijkstra P J, TenVergert E M, Van Altena R et al.. Reliability and validity of the chronic respiratory questionnaire (CRQ).  Thorax. 1994;  49 465-467
• 21 Chang J A, Curtis J R, Patrick D L, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease.  Chest. 1999;  116 1175-1182
• 22 Ware J E, Snow K K, Kosinski M et al.. SF-36 Health Survey: Manual and Interpretation Guide. Boston; Quality Metric 1993
• 23 Bowling A. Measuring Disease: A Review of Disease-Specific Quality of Life Measurement Scales. Buckingham; Open University Press 1995
• 24 Cox C E, Donohue J F, Brown C D, Kataria Y P, Judson M A. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life.  Am J Respir Crit Care Med. 2003;  168 323-329
• 25 Bergner M, Bobbitt R A, Carter W B, Gilson B S. The Sickness Impact Profile: development and final revision of a health status measure.  Med Care. 1981;  19 787-805
• 26 Jones P W, Quirk F H, Baveystock C M. The St George's Respiratory Questionnaire.  Respir Med. 1991;  85(Suppl B) 25-31 discussion 33-37
• 27 Jones P W, Bosh T K. Quality of life changes in COPD patients treated with salmeterol.  Am J Respir Crit Care Med. 1997;  155 1283-1289
• 28 Jones P W. Nedocromil Sodium Quality of Life Study Group . Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial.  Eur Respir J. 1994;  7 55-62
• 29 Jones P W, Quirk F H, Baveystock C M, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire.  Am Rev Respir Dis. 1992;  145 1321-1327
• 30 Cox C E, Donohue J F, Brown C D, Kataria Y P, Judson M A. Health-related quality of life of persons with sarcoidosis.  Chest. 2004;  125 997-1004
• 31 Wirnsberger R M, De Vries J, Jansen T L, Van Heck G L, Wouters E F, Drent M. Impairment of quality of life: rheumatoid arthritis versus sarcoidosis.  Neth J Med. 1999;  54 86-95
• 32 Antoniou K M, Tzanakis N, Tzouvelekis A et al.. Quality of life in patients with active sarcoidosis in Greece.  Eur J Intern Med. 2006;  17 421-426
• 33 Michielsen H J, De Vries J, Drent M, Peros-Golubicic T. Psychometric qualities of the Fatigue Assessment Scale in Croatian sarcoidosis patients.  Sarcoidosis Vasc Diffuse Lung Dis. 2005;  22 133-138
• 34 De Vries J, Van Heck G L, Drent M. Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption.  Women Health. 1999;  30 99-114
• 35 Gvozdenovic B S, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson M A. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis.  Respir Med. 2008;  102 1636-1642
• 36 Goracci A, Fagiolini A, Martinucci M et al.. Quality of life, anxiety and depression in sarcoidosis.  Gen Hosp Psychiatry. 2008;  30 441-445
• 37 Michielsen H J, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients.  Chest. 2006;  130 989-994
• 38 De Vries J, Drent M, Van Heck G L, Wouters E F. Quality of life in sarcoidosis: a comparison between members of a patient organisation and a random sample.  Sarcoidosis Vasc Diffuse Lung Dis. 1998;  15 183-188
• 39 Baughman R P, Sparkman B K, Lower E E. Six-minute walk test and health status assessment in sarcoidosis.  Chest. 2007;  132 207-213
• 40 Wirnsberger R M, Drent M, Hekelaar N et al.. Relationship between respiratory muscle function and quality of life in sarcoidosis.  Eur Respir J. 1997;  10 1450-1455
• 41 Spruit M A, Thomeer M J, Gosselink R et al.. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status.  Thorax. 2005;  60 32-38
• 42 Yeager H, Rossman M D, Baughman R P ACCESS Research Group et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study.  Sarcoidosis Vasc Diffuse Lung Dis. 2005;  22 147-153
• 43 Baughman R P, Iannuzzi M C, Lower E E et al.. Use of fluticasone in acute symptomatic pulmonary sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2002;  19 198-204
• 44 de Kleijn W PE, Elfferich M DP, De Vries J et al.. Fatigue in sarcoidosis: American versus Dutch patients.  Sarcoidosis Vasc Diffuse Lung Dis. 2009;  26 92-97
• 45 de Kleijn W P, De Vries J, Lower E E, Elfferich M D, Baughman R P, Drent M. Fatigue in sarcoidosis: a systematic review.  Curr Opin Pulm Med. 2009;  15 499-506
• 46 Afari N, Buchwald D. Chronic fatigue syndrome: a review.  Am J Psychiatry. 2003;  160 221-236
• 47 Drent M, Wirnsberger R M, de Vries J, van Dieijen-Visser M P, Wouters E F, Schols A M. Association of fatigue with an acute phase response in sarcoidosis.  Eur Respir J. 1999;  13 718-722
• 48 De Vries J, Michielsen H, Van Heck G L, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS).  Br J Health Psychol. 2004;  9(Pt 3) 279-291
• 49 Hoitsma E, De Vries J, van Santen-Hoeufft M, Faber C G, Drent M. Impact of pain in a Dutch sarcoidosis patient population.  Sarcoidosis Vasc Diffuse Lung Dis. 2003;  20 33-39
• 50 Hoitsma E, Faber C G, Drent M, Sharma O P. Neurosarcoidosis: a clinical dilemma.  Lancet Neurol. 2004;  3 397-407
• 51 Lower E E, Weiss K L. Neurosarcoidosis.  Clin Chest Med. 2008;  29 475-492, ix
• 52 Drent M, Verbraecken J, van der Grinten C, Wouters E. Fatigue associated with obstructive sleep apnea in a patient with sarcoidosis.  Respiration. 2000;  67 337-340
• 53 Turner G A, Lower E E, Corser B C, Gunther K L, Baughman R P. Sleep apnea in sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1997;  14 61-64
• 54 Verbraecken J, Hoitsma E, van der Grinten C P, Cobben N A, Wouters E F, Drent M. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2004;  21 137-146
• 55 Devigili G, Tugnoli V, Penza P et al.. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology.  Brain. 2008;  131(Pt 7) 1912-1925
• 56 Goldstein D S, Robertson D, Esler M, Straus S E, Eisenhofer G. Dysautonomias: clinical disorders of the autonomic nervous system.  Ann Intern Med. 2002;  137 753-763
• 57 Hoitsma E, Faber C G, van Santen-Hoeufft M, De Vries J, Reulen J P, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab.  Sarcoidosis Vasc Diffuse Lung Dis. 2006;  23 73-77
• 58 Lower E E, Harman S, Baughman R P. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.  Chest. 2008;  133 1189-1195
• 59 Chalder T, Berelowitz G, Pawlikowska T et al.. Development of a fatigue scale.  J Psychosom Res. 1993;  37 147-153
• 60 Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial.  Am J Psychiatry. 1997;  154 408-414
• 61 Lower E E, Fleishman S, Cooper A et al.. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.  J Pain Symptom Manage. 2009;  38 650-662
• 62 Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.  Arch Intern Med. 2001;  161 411-420
• 63 Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome?.  Am J Med. 2006;  119 167.e23-30
• 64 Wagner M T, Marion S D, Judson M A. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2005;  22 235
• 65 De Vries J. Quality of life assessment. In: Vingerhoets AJJM Assessment in Behavioral Medicine. Hove; Brunner-Routledge, UK 2001: 353-370
• 66 Baughman R P, Drent M, Kavuru M Sarcoidosis Investigators et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.  Am J Respir Crit Care Med. 2006;  174 795-802
• 67 Rossman M D, Newman L S, Baughman R P et al.. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2006;  23 201-208
• 68 Judson M A, Silvestri J, Hartung C, Byars T, Cox C E. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2006;  23 51-57
• 69 Baughman R P, Judson M A, Lower E E et al.. Inhaled iloprost for sarcoidosis associated pulmonary hypertension.  Sarcoidosis Vasc Diffuse Lung Dis. 2009;  26 110-120